Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Antibacterial Resistance in Patients with Hematopoietic Stem Cell Transplantation.

Alp S, Akova M.

Mediterr J Hematol Infect Dis. 2017 Jan 1;9(1):e2017002. doi: 10.4084/MJHID.2017.002. eCollection 2017. Review.

2.
3.

WSES guidelines for management of Clostridium difficile infection in surgical patients.

Sartelli M, Malangoni MA, Abu-Zidan FM, Griffiths EA, Di Bella S, McFarland LV, Eltringham I, Shelat VG, Velmahos GC, Kelly CP, Khanna S, Abdelsattar ZM, Alrahmani L, Ansaloni L, Augustin G, Bala M, Barbut F, Ben-Ishay O, Bhangu A, Biffl WL, Brecher SM, Camacho-Ortiz A, Caínzos MA, Canterbury LA, Catena F, Chan S, Cherry-Bukowiec JR, Clanton J, Coccolini F, Cocuz ME, Coimbra R, Cook CH, Cui Y, Czepiel J, Das K, Demetrashvili Z, Di Carlo I, Di Saverio S, Dumitru IM, Eckert C, Eckmann C, Eiland EH, Enani MA, Faro M, Ferrada P, Forrester JD, Fraga GP, Frossard JL, Galeiras R, Ghnnam W, Gomes CA, Gorrepati V, Ahmed MH, Herzog T, Humphrey F, Kim JI, Isik A, Ivatury R, Lee YY, Juang P, Furuya-Kanamori L, Karamarkovic A, Kim PK, Kluger Y, Ko WC, LaBarbera FD, Lee JG, Leppaniemi A, Lohsiriwat V, Marwah S, Mazuski JE, Metan G, Moore EE, Moore FA, Nord CE, Ordoñez CA, Júnior GA, Petrosillo N, Portela F, Puri BK, Ray A, Raza M, Rems M, Sakakushev BE, Sganga G, Spigaglia P, Stewart DB, Tattevin P, Timsit JF, To KB, Tranà C, Uhl W, Urbánek L, van Goor H, Vassallo A, Zahar JR, Caproli E, Viale P.

World J Emerg Surg. 2015 Aug 20;10:38. doi: 10.1186/s13017-015-0033-6. eCollection 2015. Review.

4.

SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model.

Baines SD, Crowther GS, Freeman J, Todhunter S, Vickers R, Wilcox MH.

J Antimicrob Chemother. 2015 Jan;70(1):182-9. doi: 10.1093/jac/dku324. Epub 2014 Sep 3.

5.

New drugs and devices from 2011 - 2012 that might change your practice.

Lex J.

West J Emerg Med. 2013 Nov;14(6):619-28. doi: 10.5811/westjem.2013.2.16210. Review.

6.

Treatment Strategies for Recurrent Clostridium difficile Infection.

Leong C, Zelenitsky S.

Can J Hosp Pharm. 2013 Nov;66(6):361-8. Review.

7.

Outpatient healthcare settings and transmission of Clostridium difficile.

Jury LA, Sitzlar B, Kundrapu S, Cadnum JL, Summers KM, Muganda CP, Deshpande A, Sethi AK, Donskey CJ.

PLoS One. 2013 Jul 24;8(7):e70175. doi: 10.1371/journal.pone.0070175. Print 2013.

8.

Is fidaxomicin worth the cost? An economic analysis.

Bartsch SM, Umscheid CA, Fishman N, Lee BY.

Clin Infect Dis. 2013 Aug;57(4):555-61. doi: 10.1093/cid/cit346. Epub 2013 May 23.

9.

Analysis of anti-Clostridium difficile activity of thuricin CD, vancomycin, metronidazole, ramoplanin, and actagardine, both singly and in paired combinations.

Mathur H, O'Connor PM, Hill C, Cotter PD, Ross RP.

Antimicrob Agents Chemother. 2013 Jun;57(6):2882-6. doi: 10.1128/AAC.00261-13. Epub 2013 Apr 9.

10.

Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection.

El Feghaly RE, Stauber JL, Deych E, Gonzalez C, Tarr PI, Haslam DB.

Clin Infect Dis. 2013 Jun;56(12):1713-21. doi: 10.1093/cid/cit147. Epub 2013 Mar 13.

11.

Association of relapse of Clostridium difficile disease with BI/NAP1/027.

Marsh JW, Arora R, Schlackman JL, Shutt KA, Curry SR, Harrison LH.

J Clin Microbiol. 2012 Dec;50(12):4078-82. doi: 10.1128/JCM.02291-12. Epub 2012 Oct 10.

12.

In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile.

Mascio CT, Mortin LI, Howland KT, Van Praagh AD, Zhang S, Arya A, Chuong CL, Kang C, Li T, Silverman JA.

Antimicrob Agents Chemother. 2012 Oct;56(10):5023-30. doi: 10.1128/AAC.00057-12. Epub 2012 Jul 16.

13.

Models for the study of Clostridium difficile infection.

Best EL, Freeman J, Wilcox MH.

Gut Microbes. 2012 Mar-Apr;3(2):145-67. doi: 10.4161/gmic.19526. Epub 2012 Mar 1. Review.

14.
15.

Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.

Citron DM, Tyrrell KL, Merriam CV, Goldstein EJ.

Antimicrob Agents Chemother. 2012 May;56(5):2493-503. doi: 10.1128/AAC.06305-11. Epub 2012 Jan 30.

16.

A novel agent effective against Clostridium difficile infection.

Dvoskin S, Xu WC, Brown NC, Yanachkov IB, Yanachkova M, Wright GE.

Antimicrob Agents Chemother. 2012 Mar;56(3):1624-6. doi: 10.1128/AAC.06097-11. Epub 2011 Dec 27.

17.

Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.

Goldstein EJ, Citron DM, Sears P, Babakhani F, Sambol SP, Gerding DN.

Antimicrob Agents Chemother. 2011 Nov;55(11):5194-9. doi: 10.1128/AAC.00625-11. Epub 2011 Aug 15.

18.

Epidemiology of clostridium difficile and vancomycin-resistant Enterococcus colonization in patients on a spinal cord injury unit.

Dumford DM 3rd, Nerandzic M, Chang S, Richmond MA, Donskey C.

J Spinal Cord Med. 2011;34(1):22-7.

19.

Risk Factors for Treatment Failure and Recurrence after Metronidazole Treatment for Clostridium difficile-associated Diarrhea.

Jung KS, Park JJ, Chon YE, Jung ES, Lee HJ, Jang HW, Lee KJ, Lee SH, Moon CM, Lee JH, Shin JK, Jeon SM, Hong SP, Kim TI, Kim WH, Cheon JH.

Gut Liver. 2010 Sep;4(3):332-7. doi: 10.5009/gnl.2010.4.3.332. Epub 2010 Sep 24.

20.

The changing epidemiology of Clostridium difficile infections.

Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, Kuijper EJ, Wilcox MH.

Clin Microbiol Rev. 2010 Jul;23(3):529-49. doi: 10.1128/CMR.00082-09. Review.

Supplemental Content

Support Center